Payment overview · 2025
General Payments
$552.83
34 reported records · 8 companies
Healthcare provider profile · identity verified
Michael D Jones, MD
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology · MEXICO, MO · NPI 1972523991
Verified facts
What the public records show
CMS Open Payments records show Michael D Jones, MD received $552.83 in general payments during 2025 across 34 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $176.75 | 32.0% | 11 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $138.15 | 25.0% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.77 | 9.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.46 | 8.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.35 | 8.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.44 | 6.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.92 | 5.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.99 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.83 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $176.75 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $138.15 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 95 |
| Furosemide | Furosemide | 542 | 96 |
| Eliquis | Apixaban | 533 | 53 |
| Gabapentin | Gabapentin | 457 | 67 |
| Trazodone Hcl | Trazodone Hcl | 453 | 78 |
| Metformin Hcl | Metformin Hcl | 430 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 77 |
| Lisinopril | Lisinopril | 402 | 74 |
| Sertraline Hcl | Sertraline Hcl | 391 | 56 |
| Mirtazapine | Mirtazapine | 382 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 365 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 69 |
| Potassium Chloride | Potassium Chloride | 353 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 333 | 56 |
| Benztropine Mesylate | Benztropine Mesylate | 310 | 46 |
| Estradiol | Estradiol | 301 | 76 |
| Quetiapine Fumarate | Quetiapine Fumarate | 301 | 55 |
| Divalproex Sodium | Divalproex Sodium | 296 | 43 |
| Olanzapine | Olanzapine | 283 | 38 |
| Losartan Potassium | Losartan Potassium | 259 | 37 |
| Donepezil Hcl | Donepezil Hcl | 252 | 37 |
| Famotidine | Famotidine | 240 | 47 |
| Omeprazole | Omeprazole | 196 | 36 |
| Buspirone Hcl | Buspirone Hcl | 194 | 26 |
| Topiramate | Topiramate | 189 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 34 |
| Risperidone | Risperidone | 186 | 27 |
| Xarelto | Rivaroxaban | 184 | 16 |
| Aripiprazole | Aripiprazole | 177 | 25 |
| Jardiance | Empagliflozin | 164 | 14 |
| Carvedilol | Carvedilol | 159 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 158 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 27 |
| Haloperidol | Haloperidol | 152 | 31 |
| Simvastatin | Simvastatin | 144 | 22 |
| Meloxicam | Meloxicam | 142 | 25 |
| Memantine Hcl | Memantine Hcl | 140 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 139 | 24 |
| Imipramine Hcl | Imipramine Hcl | 136 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 135 | 26 |
| Tramadol Hcl | Tramadol Hcl | 135 | 20 |
| Prazosin Hcl | Prazosin Hcl | 132 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 23 |
| Clozapine | Clozapine | 126 | 11 |
| Lorazepam | Lorazepam | 124 | 28 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 121 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 22 |
| Lithium Carbonate | Lithium Carbonate | 120 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 120 | 15 |
| Prednisone | Prednisone | 120 | 36 |
| Propranolol Hcl | Propranolol Hcl | 119 | 22 |
| Levetiracetam | Levetiracetam | 117 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 104 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 39 |
| Allopurinol | Allopurinol | 103 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 16 |
| Warfarin Sodium | Warfarin Sodium | 102 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 101 | 11 |
| Pregabalin | Pregabalin | 101 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 25 |
| Clonazepam | Clonazepam | 92 | 18 |
| Lamotrigine | Lamotrigine | 90 | suppressed |
| Spironolactone | Spironolactone | 89 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 86 | 17 |
| Finasteride | Finasteride | 86 | 14 |
| Entresto | Sacubitril/Valsartan | 85 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 40 |
| Ondansetron Odt | Ondansetron | 84 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 81 | 15 |
| Azithromycin | Azithromycin | 80 | 46 |
| Divalproex Sodium Er | Divalproex Sodium | 80 | suppressed |
| Baclofen | Baclofen | 74 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 12 |
| Cephalexin | Cephalexin | 72 | 42 |
| Farxiga | Dapagliflozin Propanediol | 72 | suppressed |
| Fluconazole | Fluconazole | 71 | 41 |
| Glucagon Emergency Kit | Glucagon | 71 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 30 |
| Atenolol | Atenolol | 69 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 69 | 12 |
| Nystatin | Nystatin | 68 | 34 |
| Nystop | Nystatin | 66 | 22 |
| Lovastatin | Lovastatin | 65 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 65 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 64 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 13 |
| Midodrine Hcl | Midodrine Hcl | 57 | 13 |
| Ibuprofen | Ibuprofen | 56 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 54 | suppressed |
| Paliperidone Er | Paliperidone | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 17 |
| Levofloxacin | Levofloxacin | 51 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 23 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Sodium Chloride | 0.9 % Sodium Chloride | 39 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Latanoprost | Latanoprost | 38 | 13 |
| Cryselle | Norgestrel-Ethinyl Estradiol | 37 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 14 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 19 |
| Tamoxifen Citrate | Tamoxifen Citrate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Ketoconazole | Ketoconazole | 31 | 14 |
| Lacosamide | Lacosamide | 31 | suppressed |
| Olanzapine Odt | Olanzapine | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 30 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 21 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 29 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Ingrezza | Valbenazine Tosylate | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Trospium Chloride | Trospium Chloride | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Invokana | Canagliflozin | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 18 |
| Briviact | Brivaracetam | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Gemtesa | Vibegron | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 11 |
| Estradiol (Once Weekly) | Estradiol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 20 | 15 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Unifine Pentips Plus | Pen Needle, Diabetic | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Aristada | Aripiprazole Lauroxil | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 13 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.83 · 34 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, Auvelity, CAPLYTA, FANAPT, INGREZZA, Korlym, REXULTI, UZEDY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error